A Study of Oral Ibogaine in Opioid Withdrawal

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Study DMX-IB 201 is a Phase 1/2a study of ibogaine consisting of an initial single ascending dose escalation stage to determine the maximum tolerated dose (MTD) or treat-to-target dose (TTD) in healthy volunteers, followed by a randomized, double-blind, placebo-controlled proof of concept stage to demonstrate the efficacy, safety and tolerability of the selected dose in opioid-dependent patients who seek medically supervised opioid withdrawal
Epistemonikos ID: 87747a8f2b5a5ca691170893211e63f4d1ba172e
First added on: May 09, 2024